Conmed signals $150M share repurchase program and narrows 2025 revenue guidance amid strategic portfolio focus

Earnings Call Insights: CONMED Corporation (CNMD) Q3 2025

MANAGEMENT VIEW

* Patrick Beyer, President and CEO, reported total sales of approximately $338 million for the quarter, citing "6.7% growth year-over-year as reported and 6.3% growth in constant currency." He highlighted that "performance was led by general surgery, which grew 6.9% globally on a constant currency basis and orthopedics, which delivered 5.3% constant currency growth globally."
* Beyer emphasized growth platforms, stating, "BioBrace continues to be a cornerstone of our sports medicine strategy. Quarter 3 growth was driven by expanding clinical adoption and strong surgeon engagement... BioBrace is now used across 70-plus distinct procedures."
* The CEO highlighted Buffalo Filter and AirSeal as key general surgery platforms, with Buffalo Filter experiencing "sustained momentum driven by expanding legislative mandates, heightened awareness of surgical smoke risks and deeper integration to hospital protocols."
* Beyer announced a strategic shift in capital allocation: "As part of our evolving capital allocation framework, we are transitioning the cash return to shareholders from our legacy dividend policy to prioritize share repurchases. The Board has authorized a new $150 million share repurchase program."
* Todd Garner, Executive VP of Finance & CFO, stated, "For the third quarter of 2025, total sales increased 6.3% year-over-year. The quarter included one extra selling day, which we estimate contributed between 100 and 150 basis points to growth."
* Garner added, "Adjusted gross margin for the third quarter was 56.1%, which was ahead of our projection due to positive sales mix."

OUTLOOK

* Garner provided Q4 revenue guidance of between $363 million and $370 million, representing mid-single-digit constant currency growth with about 100 basis points of tailwind from currency.
* Full year 2025 reported revenue guidance was narrowed to a range of $1.365 billion to $1.372 billion.
* Adjusted EPS guidance for Q4 is $1.30 to $1.35, putting full year guidance at $4.48 to $4.53, compared to the prior guidance range of $4.40 to $4.55.
* Management stated, "We continue to project adjusted gross margin in Q4 to be in the mid-55% range, inclusive of about 150 basis points of headwind from the new tariffs in 2025."

FINANCIAL RESULTS

* Total sales for Q3 were approximately $338 million, with U.S. sales up 5.9% and international sales up 6.8% year-over-year.
* Worldwide orthopedic sales rose 5.3%; general surgery sales increased 6.9% globally.
* Adjusted net income for the quarter was $33.4 million; adjusted diluted EPS was $1.08, up 2.9% compared to the prior year quarter.
* Cash balance at September 30 was $38.9 million, with long-term debt at $853.0 million and a leverage ratio of 3.0x.
* Cash flow from operations for the quarter was $53.7 million; capital expenditures were $5.2 million.

Q&A

* Lilia-Celine Lozada, JPMorgan: Asked about the dividend suspension and future M&A or debt paydown. CFO Garner responded, "No other changes. You should not expect any other changes... Now that we've reached the 3.0 mark... we thought now would be a good time to make that exchange and fit in more with the peer set and what's expected in our market and in our size and return cash to shareholders through share repurchases instead of dividends."
* Anna Runci, Piper Sandler: Inquired about tariff headwinds. Garner clarified, "This has been consistent... tariffs go into our manufacturing variances, which travel with inventory and then get released in the external P&L with that revenue, which for us is about a 6-month deferral."
* Vikramjeet Chopra, Wells Fargo: Queried about AirSeal adoption and supply chain improvements. Beyer explained, "In quarter 3, we had record manufacturing volumes for our orthopedic products. And also, we had a record reduction in the critical SKUs associated to getting our orthopedics business back on offense."
* Young Li, Jefferies: Asked about AirSeal's non-robotic opportunity and BioBrace's procedure expansion. Beyer replied, "The beauty of BioBrace is it has a clinical indication where tissue weakness exists... that's just the expansion from the 50s to the 60s to 70s is just a natural evolution of time where surgeons continue to see clinical application for it."
* Gracia Mahoney, BofA: Questioned margin outlook. Garner stated, "We have communicated that we expect to save tens of millions of dollars overall. Of course, there's things that work against that, right? The new tariffs, of course, are going to be worked against that."
* Joseph Conway, Needham: Sought color on orthopedic improvement. Beyer pointed to BioBrace and "improving reduction in back order and improving service levels on the operations side are allowing us to take some incremental steps forward in growth."

SENTIMENT ANALYSIS

* Analysts focused on capital allocation strategy, supply chain improvements, tariff impacts, and product adoption, with a generally neutral to slightly positive tone based on the clarity of management's responses.
* Management maintained a confident and methodical tone during prepared remarks, emphasizing progress, while in Q&A, responses were consistently clear but occasionally cautious, particularly regarding the timing of improvements and future guidance.
* Compared to the previous quarter, management's tone remained confident but showed heightened emphasis on strategic transformation and operational discipline, while analysts maintained a steady focus on recurring operational and capital allocation themes.

QUARTER-OVER-QUARTER COMPARISON

* The capital allocation shift from dividends to share repurchases is a new development in Q3, whereas Q2 focused on debt reduction and operational stabilization.
* Guidance for full year revenue was narrowed in Q3, with a similar adjusted EPS range to Q2, though Q3 offered a clearer transition in capital allocation priorities.
* Supply chain discussions in Q3 highlighted record manufacturing volumes and SKU reduction, whereas in Q2, much of the focus was on the initiation of operational improvements.
* Analysts continued to probe on product adoption, supply chain progress, and margin outlook, with recurring interest in BioBrace and AirSeal's market potential.
* Management's confidence in core platforms and transformation work was consistent, but Q3 featured more explicit forward-looking actions like the new share repurchase program.

RISKS AND CONCERNS

* Key challenges include ongoing supply chain recovery, response to new tariffs, and the pacing of orthopedic market share recovery.
* Management's mitigation strategies include systems enhancements, procurement, planning, and production improvements, as well as operational savings initiatives.
* Analysts flagged potential headwinds from tariff expenses and market share recapture timing, with management emphasizing steady progress but not declaring full resolution.

FINAL TAKEAWAY

CONMED's third quarter marked significant progress in strategic focus, operational execution, and capital allocation. With robust sales growth in general surgery and orthopedics, expanding clinical adoption of BioBrace, and sustained momentum in platforms like Buffalo Filter and AirSeal, the company is sharpening its portfolio for long-term growth. The transition from dividend payments to a $150 million share repurchase program reflects a commitment to flexible, shareholder-aligned capital deployment, while ongoing operational improvements and a narrowed revenue guidance underscore disciplined execution heading into year-end.

Read the full Earnings Call Transcript [https://seekingalpha.com/symbol/cnmd/earnings/transcripts]

MORE ON CONMED

* CONMED Corporation (CNMD) Q3 2025 Earnings Call Transcript [https://seekingalpha.com/article/4838843-conmed-corporation-cnmd-q3-2025-earnings-call-transcript]
* CONMED Corporation 2025 Q3 - Results - Earnings Call Presentation [https://seekingalpha.com/article/4838770-conmed-corporation-2025-q3-results-earnings-call-presentation]
* Conmed Constrained By Execution, Tariffs, And Sector Sentiment [https://seekingalpha.com/article/4819878-conmed-stock-constrained-by-execution-tariffs-and-sector-sentiment-reiterate-hold]
* CONMED Non-GAAP EPS of $1.08 beats by $0.03, revenue of $337.9M beats by $3.14M [https://seekingalpha.com/news/4516459-conmed-non-gaap-eps-of-1_08-beats-by-0_03-revenue-of-337_9m-beats-by-3_14m]
* Seeking Alpha’s Quant Rating on CONMED [https://seekingalpha.com/symbol/CNMD/ratings/quant-ratings]